Janux Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Janux Therapeutics, Inc. (JANX) reported Debt Securities, Available-for-sale, Unrealized Loss of $300.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2022-03-18
- Janux Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2021 was $300.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|
| 2021-12-31 | $300.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |